Faisal Khurshid
Stock Analyst at Leerink Partners
(0.71)
# 3,670
Out of 4,829 analysts
19
Total ratings
28.57%
Success rate
-18.36%
Average return
Main Sectors:
Stocks Rated by Faisal Khurshid
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRWD Ironwood Pharmaceuticals | Maintains: Market Perform | $3 → $1 | $0.71 | +41.00% | 2 | Apr 14, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | $45 | $14.10 | +219.15% | 1 | Apr 8, 2025 | |
| NRIX Nurix Therapeutics | Initiates: Market Perform | $16 | $9.50 | +68.42% | 1 | Mar 17, 2025 | |
| STTK Shattuck Labs | Initiates: Outperform | $4 | $0.95 | +321.99% | 1 | Mar 17, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Market Perform | $33 → $2 | $1.41 | +41.84% | 2 | Mar 3, 2025 | |
| ATYR aTyr Pharma | Initiates: Outperform | $16 | $3.28 | +387.80% | 1 | Feb 18, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $60 | $30.07 | +99.53% | 2 | Dec 27, 2024 | |
| ANIP ANI Pharmaceuticals | Initiates: Outperform | $80 | $66.30 | +20.66% | 1 | Dec 11, 2024 | |
| ZURA Zura Bio | Initiates: Outperform | $15 | $1.21 | +1,139.67% | 1 | Nov 4, 2024 | |
| TRVI Trevi Therapeutics | Assumes: Outperform | $7 | $6.60 | +6.06% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $45 | $16.66 | +170.19% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $24 | $25.31 | -5.18% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.18 | +493.22% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $4.56 | +75.44% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $5 | $1.01 | +395.05% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $11 | $6.90 | +59.42% | 1 | Mar 21, 2023 |
Ironwood Pharmaceuticals
Apr 14, 2025
Maintains: Market Perform
Price Target: $3 → $1
Current: $0.71
Upside: +41.00%
Spyre Therapeutics
Apr 8, 2025
Initiates: Outperform
Price Target: $45
Current: $14.10
Upside: +219.15%
Nurix Therapeutics
Mar 17, 2025
Initiates: Market Perform
Price Target: $16
Current: $9.50
Upside: +68.42%
Shattuck Labs
Mar 17, 2025
Initiates: Outperform
Price Target: $4
Current: $0.95
Upside: +321.99%
Pliant Therapeutics
Mar 3, 2025
Downgrades: Market Perform
Price Target: $33 → $2
Current: $1.41
Upside: +41.84%
aTyr Pharma
Feb 18, 2025
Initiates: Outperform
Price Target: $16
Current: $3.28
Upside: +387.80%
Kymera Therapeutics
Dec 27, 2024
Maintains: Outperform
Price Target: $60
Current: $30.07
Upside: +99.53%
ANI Pharmaceuticals
Dec 11, 2024
Initiates: Outperform
Price Target: $80
Current: $66.30
Upside: +20.66%
Zura Bio
Nov 4, 2024
Initiates: Outperform
Price Target: $15
Current: $1.21
Upside: +1,139.67%
Trevi Therapeutics
Sep 9, 2024
Assumes: Outperform
Price Target: $7
Current: $6.60
Upside: +6.06%
Sep 9, 2024
Assumes: Outperform
Price Target: $45
Current: $16.66
Upside: +170.19%
Sep 9, 2024
Initiates: Market Perform
Price Target: $24
Current: $25.31
Upside: -5.18%
Sep 9, 2024
Initiates: Outperform
Price Target: $7
Current: $1.18
Upside: +493.22%
Sep 9, 2024
Assumes: Outperform
Price Target: $8
Current: $4.56
Upside: +75.44%
Sep 9, 2024
Assumes: Outperform
Price Target: $5
Current: $1.01
Upside: +395.05%
Mar 21, 2023
Initiates: Outperform
Price Target: $11
Current: $6.90
Upside: +59.42%